Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity

S. J. Langley, S. Goldthorpe, A. Custovic, A. A. Woodcock (Manchester, United Kingdom)

Source: Annual Congress 2001 - Mechanisms of allergen immunotherapy
Session: Mechanisms of allergen immunotherapy
Session type: Oral Presentation
Number: 3230
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. J. Langley, S. Goldthorpe, A. Custovic, A. A. Woodcock (Manchester, United Kingdom). Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity. Eur Respir J 2001; 16: Suppl. 31, 3230

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Correlation between nasal eosinophilic inflammation and bronchial reactivity to methacholine in allergic children sensitized to house dust mites (HDM)
Source: Eur Respir J 2002; 20: Suppl. 38, 172s
Year: 2002

Sensitisation to house dust mite: its association with bronchial hyperresponsiveness and lung function in asthmatic children
Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma
Year: 2009

The association of adult bronchial responsiveness with IgE sensitisation and exposure to cat and house dust mite allergen
Source: Eur Respir J 2006; 28: Suppl. 50, 145s
Year: 2006

OPURIT: Omalizumab-protected ultra rush specific immunotherapy in severe asthmatic patients with house dust mite allergy
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011


Low exposure to inhaled formaldehyde: effect on allergen bronchial response in asthmatics sensitized to mite
Source: Eur Respir J 2006; 28: Suppl. 50, 592s
Year: 2006

Phospho-STAT-6 levels in nasal scrapings of asthmatic patients increases following nasal challenge with grass but not house dust mite allergen
Source: Annual Congress 2009 - Novel mechanisms in the pathogenesis of asthma
Year: 2009


Exposure to higher levels of house dust mite allergen and endotoxin is not associated with respiratory symptoms and severity of AHR in older asthmatics
Source: Eur Respir J 2002; 20: Suppl. 38, 454s
Year: 2002

Circulating platelets activity in patients sensitised to house dust mite suffering from persistent allergic rhinitis with or without asthma symptoms
Source: Eur Respir J 2005; 26: Suppl. 49, 590s
Year: 2005

Effect of house dust mite sublingual immunotherapy on airway inflammation and remodeling in allergic asthma with rhinitis
Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases
Year: 2019




Calcaratarin D attenuates house dust mite-induced allergic asthma
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Year: 2021


Importance of large particle in bronchial challenge test in mite allergic asthmatics
Source: Eur Respir J 2004; 24: Suppl. 48, 588s
Year: 2004

Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects
Source: Eur Respir J 2002; 20: Suppl. 38, 57s
Year: 2002

Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis
Source: Eur Respir J 2006; 28: Suppl. 50, 438s
Year: 2006

Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021


Exhaled NO in steroid naive house dust mite allergic asthmatics
Source: Eur Respir J 2007; 30: Suppl. 51, 617s
Year: 2007

Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis
Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials
Year: 2021


House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma
Source: Virtual Congress 2020 – Management of allergy, asthma and COPD
Year: 2020


Levels of house dust mites (HDM) in homes of patients with bronchial asthma (BA) and the airway inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 281s
Year: 2001

Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007


Degranulation of basophils after incubation with allergen in chidren with pollinosis and dust mite allergy
Source: Eur Respir J 2001; 18: Suppl. 33, 450s
Year: 2001